U
RIGL icon

UBS’s Rigel Pharmaceuticals RIGL Stock Holding History

UBS’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30
Closed -$1K – 10741
2014
Q1 		$1K Buy
+30
New +$1.07K ﹤0.01% 10226
2013
Q4 		– Sell
-200
Closed -$7K – 10702
2013
Q3 		$7K Sell
200
-50
-20% -$1.82K ﹤0.01% 9138
2013
Q2 		$8K Buy
+250
New +$11.3K ﹤0.01% 8861

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS's RIGL Position: Q1 2014 in Review

UBS sold out of Rigel Pharmaceuticals (RIGL) in Q1 2014, closing a stake of 500 shares — an estimated $17.8K sold.

UBS first reported a position in RIGL in Q2 2013 and held it in 2 quarters. The position peaked at $73K in Q2 2013. 110 funds tracked by Wall St. Rank hold RIGL as of Q1 2014.

  • UBS reported no remaining Rigel Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • UBS sold 500 Rigel Pharmaceuticals shares in Q1 2014, an estimated $17.8K.
  • UBS first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • UBS's Rigel Pharmaceuticals position peaked at $73K in Q2 2013.
  • 110 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2014.

Based on UBS's 13F filing for Q1 2014, filed 15 May 2014.